Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Bologna – page 10

906 clinical trials in Bologna, Italy across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Bologna at a glance
906
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

906 trials in Bologna

Open in trial search

Acute leukaemia

Recruiting

A study of enzomenib in adult patients with relapsed or refractory acute leukemia, including those with MLL rearrangement or NPM1 mutation.

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Sumitomo Pharma America Inc.

Metabolic dysfunction-associated liver disease

Recruiting

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.

Gastrointestinal cancer metastatic

Recruiting

Study of GSK6042981 compared to sunitinib for patients with gastrointestinal stromal tumors that spread or cannot be removed after imatinib treatment

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sunitinib
  • Sponsor:Glaxosmithkline Research & Development Limited

Cardiac failure+1

Recruiting

A study of finerenone with standard treatment for children and young adults from birth to 18 years with heart failure and left ventricular systolic dysfunction

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Cardiac failure+1

Recruiting

A study of finerenone added to standard treatment in children aged 6 months to under 18 years with heart failure and reduced left heart pumping function

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

HER2 positive endometrial cancer

Recruiting

Study of Trastuzumab Deruxtecan Versus Chemotherapy as Additional Treatment After Surgery for Patients with HER2-Positive Endometrial Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Cardiac amyloidosis

Recruiting

A study of coramitug compared to placebo for people with heart failure caused by transthyretin amyloid cardiomyopathy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Coramitug
  • Sponsor:Novo Nordisk A/S

Parkinson's disease

Recruiting

A study comparing prasinezumab with placebo for people with early-stage Parkinson's disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Prasinezumab
  • Sponsor:F. Hoffmann-La Roche AG

Myasthenia gravis

Recruiting

Study of oral cladribine compared to placebo for patients with generalized myasthenia gravis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cladribine
  • Sponsor:Merck Healthcare KGaA

Neoplasm malignant+2

Recruiting

A study of EP0031 and drug combination for patients with advanced cancers having changes in the RET gene

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Ellipses Pharma Limited

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

A study to test if empasiprubart can improve function and is safe for adults with chronic inflammatory demyelinating polyneuropathy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Hepatocellular carcinoma

Recruiting

A study testing visugromab, nivolumab, and lenvatinib for patients with advanced liver cancer that cannot be removed by surgery after previous treatment failed

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:CatalYm GmbH

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Bologna

What the registry says about research in the country

01 Hematological Disorders

Innovative research focusing on Immune Thrombocytopenia and various forms of blood cancers including Acute Myeloid Leukemia and Multiple Myeloma. These trials aim to evaluate novel therapeutic approaches and combination treatments.

  • Blood Disorders
  • Leukemia Research
  • Immunology Studies

Studies include evaluation of new compounds and their safety profiles in treating various blood-related conditions.

02 Gastrointestinal Research

Comprehensive studies on inflammatory bowel conditions, focusing on Crohn's Disease and Ulcerative Colitis. Research aims to develop more effective treatments for patients with moderate to severe disease activity.

  • Inflammatory Bowel Disease
  • Treatment Response
  • Disease Management

Trials evaluate both induction therapy and long-term treatment options for gastrointestinal conditions.

03 Neurological Conditions

Investigation of treatments for sleep disorders including Narcolepsy and Idiopathic Hypersomnia, along with research into Chronic Inflammatory Demyelinating Polyneuropathy.

  • Sleep Disorders
  • Neurological Diseases
  • Treatment Safety

Focus on developing safer and more effective therapies for various neurological conditions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.